1245506-62-0

Basic information

• Product Name: 2-Chloro-5-hydroxy-4-MethylpyriMidine
• Synonyms: 2-Chloro-5-hydroxy-4-MethylpyriMidine;2-Chloro-4-methylpyrimidin-5-ol;2-chloro-4-methyl-5-Pyrimidinol
• CAS NO: 1245506-62-0
• Molecular Formula: C₅H₅ClN₂O
• Molecular Weight: 144.559
• Mol File: 1245506-62-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-Chloro-5-hydroxy-4-MethylpyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-5-hydroxy-4-MethylpyriMidine(1245506-62-0)
• EPA Substance Registry System: 2-Chloro-5-hydroxy-4-MethylpyriMidine(1245506-62-0)

Safety Data

• Hazardous Substances Data: 1245506-62-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-5-hydroxy-4-MethylpyriMidine is utilized as an intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a key component in the development of new drugs, particularly those targeting specific biological pathways or diseases.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Chloro-5-hydroxy-4-MethylpyriMidine serves as an intermediate in the production of pesticides and other crop protection agents. Its role in these applications is to contribute to the effectiveness of these products, ensuring the protection of crops from pests and diseases, thereby supporting agricultural productivity.

Upstream product

• 1245506-61-9 2-chloro-5-methoxy-4-methylpyrimidine 

Downstream Products

• 1351338-57-2 (3R,4S)-4-(2,5-difluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}pyrrolidin-3-ylamine p-toluenesulfonate 
• 1351345-54-4 ((3R,4S)-4-(2,5-difluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}pyrrolidin-3-yl)carbamic acid tert-butyl ester 
• 1351338-59-4 (3R,4S)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-ylamine p-toluenesulfonate 
• 1351345-55-5 [(3R,4S)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1369766-60-8 5-Benzyloxy-2-chloro-4-methylpyrimidine 
• 1369766-63-1 5-Benzyloxy-2-ethyl-4-methylpyrimidine 
• 1369768-93-3 {(1R,2S)-2-{[(2-chloro-4-methylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)cyclopropyl}methanol 
• 1369768-94-4 (1R,2S)-2-{[(2-chloro-4-methylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)cyclopropanecarbaldehyde 
• 1369768-95-5 (1R,2S)-2-{[(2-chloro-4-methylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)cyclopropanecarboxylic acid 

Relevant articles and documents

CYCLOHEXYL ACID PYRAZOLE AZINES AS LPA ANTAGONISTS

The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

CYCLOHEXYL ACID PYRAZOLE AZOLES AS LPA ANTAGONISTS

The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

CYCLOPROPANE COMPOUND

A cyclopropane compound represented by the following formula (A) or a pharmaceutically acceptable salt thereof has orexin receptor antagonism, and therefore has a potencial of usefulness for the treatment of sleep disorder for which orexin receptor antagonism is effective, for example, insomnia: wherein Q represents —CH— or a nitrogen atom, R1a and R1b each independently represent a C1-6 alkyl group and the like, R1c represents a hydrogen atom and the like, R2a, R2b, R2c and R2d each independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group and the like, R3a, R3b and R3c each independently represent a hydrogen atom, a halogen atom and the like, and R3d represents a hydrogen atom and the like.

CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS

Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR119. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention is directed to therapeutic compotmds of the following formula (I) which have activity as agonists of GPR 119 and are useful for the treatment of metabolic disorders including type II diabetes.